CARA THERAPEUTICS, INC. (NASDAQ:CARA) Files An 8-K Regulation FD Disclosure
Item 7.01
(d) Exhibits
| 99.1 | Presentation dated December 2019. |
Cara Therapeutics, Inc. Exhibit
EX-99.1 2 tm1926281d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Targeting Pruritus with Novel Peripherally – Restricted Kappa Agonist Therapeutics December 2019 Forward Looking Statements 2 This presentation contains certain forward – looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases,…
To view the full exhibit click here
About CARA THERAPEUTICS, INC. (NASDAQ:CARA)
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Company is engaged in developing product candidates that focus on the body’s peripheral nervous system. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845, and CR701. The Company’s I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. The Company is developing an oral version of CR845 for the treatment of moderate-to-severe acute and chronic pain. The Company’s CR701 is a peripherally-restricted, mixed-CB1/CB2 receptor agonist that interacts with cannabinoid receptor subtypes, with no off-target activities. CR701 is in preclinical-stage of development.
